Loading clinical trials...
Loading clinical trials...
A Randomized, Controlled, Blinded, Parallel Group Study of the Safety and Efficacy of APC-0101 (SF-RI 1 Surfactant for Inhalation Combined With a Dedicated Delivery System) in Preterm Infants With Respiratory Distress Syndrome
Conditions
Interventions
APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system)
Control
Locations
12
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Jacobs Medical Center
La Jolla, California, United States
UF Health Jacksonville
Jacksonville, Florida, United States
Advent Health
Orlando, Florida, United States
Memorial Hospital of South Bend
South Bend, Indiana, United States
Goryeb Children's Hospital
Morristown, New Jersey, United States
Start Date
September 24, 2025
Primary Completion Date
May 1, 2027
Completion Date
May 1, 2029
Last Updated
April 14, 2026
NCT04565665
NCT07504731
NCT06703073
NCT07344714
NCT07123961
NCT07450846
Lead Sponsor
Aerogen Pharma Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions